Øystein Rekdal (CEO in Lytix Biopharma) has accepted an invitation to give an oral presentation at Esmo Immuno-Oncology Congress in Geneva, Switzerland.
Under the session name ‘New vaccine technologies and administration modalities’, Øystein will give his presentation ‘Addressing heterogeneity: A hot topic’.